TABLE 4-5Average Number of Adverse Effects from Not Receiving Research Inputs, Academic Respondents by Research Goal and for Pathways and Industry Respondents

Random Sample Research Goal Pathways Industry
Drug Discovery Basic Research Other CTLA4 EGF NF-kB
Academic Supplier
Delay >1 month 0.68 0.98 0.69 0.33 0.83 1.2 2.85 0.78
Change Research Approach 0.56 0.89 0.54 0.3 0.45 0.7 2.24 0.68
Abandon 0.22 0.07 0.24 0.21 0.27 0.2 0.62 0.39
Make In-house 0.67 0.88 0.65 0.59 0.93 1.2 2.29 1.01
Industry Supplier
Delay >1 month 0.4 0.75 0.39 0.18 1.02 1.1 0.87 0.35
Change Research Approach 0.46 0.66 0.42 0.56 0.68 0.7 1.66 0.49
Abandon 0.27 0.08 0.3 0.26 0.58 0.9 0.28 0.32
Make In-house 0.31 0.44 0.28 0.47 0.69 0.8 0.71 0.33
Respondents 242 24 195 23 21 24 26 62

SOURCE: Walsh et al., 2005.

From: 4, Trends in the Patenting and Licensing of Genomic and Protein Inventions and Their Impact on Biomedical Research

Cover of Reaping the Benefits of Genomic and Proteomic Research
Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health.
National Research Council (US) Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation; Merrill SA, Mazza AM, editors.
Washington (DC): National Academies Press (US); 2006.
Copyright © 2006, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.